These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21361055)

  • 21. Migraine headache prophylaxis and treatment with low-dose mirtazapine.
    Lévy E; Margolese HC
    Int Clin Psychopharmacol; 2003 Sep; 18(5):301-3. PubMed ID: 12920393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mirtazapine and restless leg syndrome: a case report.
    Bonin B; Vandel P; Kantelip JP
    Therapie; 2000; 55(5):655-6. PubMed ID: 11201984
    [No Abstract]   [Full Text] [Related]  

  • 23. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
    Hannan N; Hamzah Z; Akinpeloye HO; Meagher D
    J Psychopharmacol; 2007 Mar; 21(2):161-4. PubMed ID: 17329295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
    Masana M; Castañé A; Santana N; Bortolozzi A; Artigas F
    Neuropharmacology; 2012 Sep; 63(4):675-84. PubMed ID: 22652058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of mirtazapine on salivary cortisol in depressed patients.
    Laakmann G; Hennig J; Baghai T; Schüle C
    Neuropsychobiology; 2003; 47(1):31-6. PubMed ID: 12606843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
    Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of mirtazapine in patients with chronic pain and concomitant depression.
    Freynhagen R; Muth-Selbach U; Lipfert P; Stevens MF; Zacharowski K; Tölle TR; von Giesen HJ
    Curr Med Res Opin; 2006 Feb; 22(2):257-64. PubMed ID: 16466597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysthymic disorder: treatment with mirtazapine.
    Dunner DL; Hendrickson HE; Bea C; Budech CB; O'Connor E
    Depress Anxiety; 1999; 10(2):68-72. PubMed ID: 10569129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Major depressive disorder, antidepressants, and sexual dysfunction.
    Clayton AH; Montejo AL
    J Clin Psychiatry; 2006; 67 Suppl 6():33-7. PubMed ID: 16848675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.
    de Boer T
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():19-23. PubMed ID: 8930006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
    Kasai M; Shioda K; Nisijima K; Yoshino T; Iwamura T; Kato S
    Neurosci Lett; 2011 Jul; 499(1):24-7. PubMed ID: 21621587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interference in the serotoninergic and noradrenergic system. Faster out of depression].
    MMW Fortschr Med; 2001 Nov; 143(44):57. PubMed ID: 11732403
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of mirtazapine on sleep in patients with major depressive disorder.
    Dolder CR; Nelson MH; Iler CA
    Ann Clin Psychiatry; 2012 Aug; 24(3):215-24. PubMed ID: 22860241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
    Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED
    J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
    Laino CH; Fonseca C; Sterin-Speziale N; Slobodianik N; Reinés A
    Eur J Pharmacol; 2010 Dec; 648(1-3):117-26. PubMed ID: 20826148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Akathisia induced by mirtazapine after 20 years of continuous treatment.
    Markoula S; Konitsiotis S; Chatzistefanidis D; Lagos G; Kyritsis AP
    Clin Neuropharmacol; 2010; 33(1):50-1. PubMed ID: 20124786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study.
    Saiz-Ruiz J; Montes JM; Ibáñez A; Díaz M; Vicente F; Pelegrín C; Viñas R; Arias F; Carrasco JL; Ferrando L
    Hum Psychopharmacol; 2005 Aug; 20(6):435-40. PubMed ID: 16106478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and safety aspects of mirtazapine.
    Nutt DJ
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-41. PubMed ID: 12404669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.